TB Manual

1. Statistics Canada. Immigration and ethnocultural diversity: key results from the 2016 census. Statistics Canada; 2017. https:// statcan.gc.ca/n1/daily-quotidien/171025/dq171025b-eng.htm Accessed June 14, 2021.
2. Statistics Canada. Table 24-10-0005-01 International travellers entering or returning to Canada, by province of entry, seasonally Accessed May 25, 2021. doi:10.25318/2410000501-eng.
3. Magalhaes L, Carrasco C, Gastaldo Undocumented migrants in Canada: a scope literature review on health, access to services, and working conditions. J Immigr Minor Health. 2010;12(1):132– 151. doi:10.1007/s10903-009-9280-5.
4. Immigration, Refugees and Citizenship Canada. 2020 annual report to Parliament on immigration. Immigration, Refugees and Citizenship Canada; https://www.canada.ca/en/ immigration-refugees-citizenship/corporate/publications-manuals/ annual-report-parliament-immigration-2020.html. Accessed June 28, 2021.
5. LaFreniere M, Hussain H, He N, McGuire M. Tuberculosis in Canada: 2017. Can Commun Dis Rep. 2019;45(2-3):67–74. doi:14745/ccdr.v45i23a04.
6. Public Health Agency of Canada. Tuberculosis in Canada 2019, pre-release.
7. Campbell JR, Chen W, Johnston J, et al. Latent tuberculosis infection screening in immigrants to low-incidence countries: a meta-analysis. Mol  Diagn    Apr.  2015;19(2):107–117. doi:10.1007/s40291-015-0135-6.
8. Campbell JR. Reducing the Tuberculosis Burden in Migrant Populations through Latent Tuberculosis Infection Interventions: A Series of Cost-Effectiveness Analyses [Thesis/Dissertation]. University of British Columbia; https://open.library.ubc.ca/media/download/pdf/24/1.0363447/4.
9. Immigration, Refugees and Citizenship Canada. Medical inadmissibility. Government of Canada. https://www.canada.ca/en/ immigration-refugees-citizenship/ser vices/application/ medical-police/medical-exams/requirements-permanent-residents. html. Accessed September 30,
10. Immigration, Refugees and Citizenship Canada. Medical exam for permanent resident applicants. Government of Canada. https:// canada.ca/en/immigration-refugees-citizenship/services/application/medical-police/medical-exams/requirements-permanent- residents.html. Accessed August 10, 2021.
11. Immigration, Refugees and Citizenship Medical exams for visitors, students and workers. Government of Canada. https://www.canada.ca/en/immigration-refugees-citizenship/ser- vices/application/medical-police/medical-exams/requirements- temporary-residents.html. Accessed August 10, 2021.
12. Immigration, Refugees and Citizenship Canada. Find out if you need a medical exam. Immigration, Refugees and Citizenship https://www.canada.ca/en/immigration-refugees-citizen- ship/services/application/medical-police/medical-exams/ requirements-temporary-residents/country-requirements.html. Accessed August 13, 2021.
13. Immigration, Refugees and Citizenship Canada. Canadian panel member guide to immigration medical examinations Immigration, Refugees and Citizenship Canada. https://www.canada.ca/en/ immigration-refugees-citizenship/corporate/publications-manuals/ panel-members-guide.html. Accessed June 3, 2021.
14. Global Case Management System
15. Khan K, Hirji MM, Miniota J, et al. Domestic impact of tuberculosis screening among new immigrants to Ontario, Canada. CMAJ. 2015;187(16):E473–E481. doi:1503/cmaj.150011.
16. Asadi L, Heffernan C, Menzies D, Long R. Effectiveness of Canada’s tuberculosis surveillance strategy in identifying immigrants at risk of developing and transmitting tuberculosis: a population-based retrospective cohort Lancet Public Health. 2017;2(10):e450–e457. doi:10.1016/S2468-2667(17)30161-5.
17. Immigration, Refugees and Citizenship Canada. Notifying clients that they require medical Immigration, Refugees and Citizenship Canada. https://www.canada.ca/en/ immigration-refugees-citizenship/corporate/publications-manuals/ operational-bulletins-manuals/standard-requirements/ medical-requirements/surveillance-notifications/notifying-client s-that-they-require-medical-surveillance.html. Accessed August 16, 2021.
18. Immigration, Refugees and Citizenship Canada. Medical surveil- lance handout: inactive tuberculosis or other complex non-infectious   Immigration,  Refugees  and Citizen s hip  C a n ad a.  https://w w w.c a n ad a.c a/en/ immigration-refugees-citizenship/corporate/publications-manuals/ operational-bulletins-manuals/standard-requirements/ medical-requirements/tuberculosis.html. Accessed August 16, 2021.
19. Russell K, Szala J, Fisher D. Immigration related tuberculosis surveillance: getting clients to the clinic [Poster presentation – TB Public Health. Poster Forum, American Thoracic Society Conference]. Am J Resp Crit Care Med. 2008;177.
20. Alvarez GG, Gushulak B, Rumman KA, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence    BMC  Infect  Dis.  2011;11(3) doi:10.1186/1471-2334-11-3.
21. Long R, Asadi L, Heffernan C, et Is there a fundamental flaw in Canada’s post-arrival immigrant surveillance system for tu- berculosis? PLoS One. 2019;14(3):e0212706. doi:10.1371/journal. pone.0212706.
22. Campbell JR, Johnston JC, Cook VJ, Sadatsafavi M, Elwood RK, Marra F. Cost-effectiveness of latent tuberculosis infection screen- ing before immigration to low-incidence Emerg Infect Dis. 2019;25(4):661–671. doi:10.3201/eid2504.171630.
23. Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculo- sis Am J Respir Crit Care Med. 2007;175(1):75–79. doi:10.1164/rccm.200608-1178OC.
24. Creatore MI, Lam M, Wobeser WL. Patterns of tuberculosis risk over time among recent immigrants to Ontario, Canada. Int J Tuberc Lung Dis. 2005;9(6):667–672.
25. Farah MG, Meyer HE, Selmer R, Heldal E, Bjune G. Long-term risk of tuberculosis among immigrants in Norway. Int J Epidemiol. 2005;34(5):1005–1011. doi:1093/ije/dyi058.
26. Greenaway C, Sandoe A, Vissandjee B, et al. Tuberculosis: evi- dence review for newly arriving immigrants and refugees. Can Med Assoc J. 2011;183(12):E939–51. doi:1503/cmaj.090302.
27. Kristensen KL, Ravn P, Petersen JH, et al. Long-term risk of tuberculosis among migrants according to migrant status: a cohort Int J Epidemiol. 2020;49(3):776–785. doi:10.1093/ije/dyaa063.
28. Ronald LA, Campbell JR, Balshaw RF, et al. Demographic pre- dictors of active tuberculosis in people migrating to British Columbia, Canada: a retrospective cohort Can Med Assoc J. 2018;190(8):E209–E216. doi:10.1503/cmaj.170817.
29. Langlois-Klassen D, Wooldrage KM, Manfreda J, et Piecing the puzzle together: foreign-born tuberculosis in an immigrant-receiving country. Eur Respir J. 2011;38(4):895–902. doi:10.1183/09031936.00196610.
30. Talwar A, Li R, Langer AJ. Association between birth region and time to tuberculosis diagnosis among non-US-born persons in the United Emerg Infect Dis. 2021;27(6):1645–1653. doi:10.3201/eid2706.203663.
31. Menzies NA, Hill AN, Cohen T, Salomon JA. The impact of migration on tuberculosis in the United States. Int J Tuberc Lung Dis. 2018;22(12):1392–1403. doi:5588/ijtld.17.0185.
32. Dale KD, Trauer JM, Dodd PJ, Houben RMGJ, Denholm JT. Estimating long-term tuberculosis reactivation rates in Australian Clin Infect Dis. 2020;70(10):2111–2118. doi:10.1093/cid/ciz569.
33. Gupta RK, Calderwood CJ, Yavlinsky A, et al. Discovery and validation of a personalized risk predictor for incident tubercu- losis in low transmission Nat Med. 2020;26(12):1941–1949. doi:10.1038/s41591-020-1076-0.
34. Tsang CA, Langer AJ, Navin TR, Armstrong LR. Tuberculosis among foreign-born persons diagnosed ≥10 years after arrival in the United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2017;66(11):295–298. doi:15585/mmwr.mm6611a3.
35. Centers for Disease Control & Prevention. Tuberculosis among Indochinese refugees – an update. Morb Mortal Wkly Rep. 1981;30(48):603–606.
36. Enarson Active tuberculosis in Indochinese refugees in British Columbia. Can Med Assoc J. 1984;131(1):39–42.
37. Thorpe LE, Laserson K, Cookson S, et al. Infectious tuberculosis among newly arrived refugees in the United States. New Engl J Med. 2004;350(20):2105–2106. doi:1056/NEJM200405133502023.
38. Wilcke JTR, Poulsen S, Askgaard DS, Enevoldsen HK, Rønne T, Kok-Jensen A. Tuberculosis in a cohort of Vietnamese refugees after arrival in Denmark 1979-1982. Int J Tuberc Lung Dis. 1998;2(3):219–224.
39. Hadzibegovic DS, Maloney SA, Cookson ST, Oladele A. Determining TB rates and TB case burden for refugees. Int J Tuberc Lung Dis. 2005;9(4):409–414.
40. Proença R, Mattos Souza F, Lisboa Bastos M, et al. Active and latent tuberculosis in refugees and asylum seekers: a systematic review and meta-analysis. BMC Public Health. 2020;20(1):838. doi:10.1186/s12889-020-08907-y.
41. FitzGerald JM, Fanning A, Hoepnner V, Hershfield E, Kunimoto D. The Canadian Molecular Epidemiology of TB Study Group. The molecular epidemiology of tuberculosis in western Canada. Int J Tuberc Lung Dis. 2003;7(2):132–138.
42. Guthrie JL, Kong C, Roth D, et al. Molecular epidemiology of tuberculosis in British Columbia, Canada: a 10-year retrospec- tive Clin Infect Dis. 2018;66(6):849–856. doi:10.1093/cid/cix906.
43. Hernández-Garduño E, Kunimoto D, Wang L, et Predictors of clustering of tuberculosis in greater Vancouver: a molecular epidemiologic study. Can Med Assoc J. 2002;167(4):349–352.
44. Kunimoto D, Sutherland K, Wooldrage K, et al. Transmission characteristics of tuberculosis in the foreign-born and the Canadian-born population of Alberta, Int J Tuberc Lung Dis. 2004;8(10):1213–1220.
45. Guthrie JL, Marchand-Austin A, Cronin K, et al. Universal genotyping reveals province-level differences in the molecular epidemiology of PLoS One. 2019;14(4):e0214870. doi:10.1371/journal.pone.0214870.
46. Heffernan C, Barrie J, Doroshenko A, et Prompt recognition of infectious pulmonary tuberculosis is critical to achieving elimination goals: a retrospective cohort study. BMJ Open Respir Res. 2020;7(1) doi:10.1136/bmjresp-2019-000521.
47. Centers for Disease Control & Prevention. Fact sheets: the difference between latent TB infection and TB disease. Centers for Disease Controls & Prevention. https://www.cdc.gov/tb/publica- tions/factsheets/general/ltbiandactivetb.htm. Accessed August 16,
48. Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549. doi:10.1136/bmj.m549.
49. Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in N  Engl  J  Med.  2018;379(5):440–453.  doi:10.1056/NEJMoa1714283.
50. Ronald LA, FitzGerald JM, Bartlett-Esquilant G, et al. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and Eur Respir J. 2020;55(3):1902048. doi:10.1183/13993003.02048-2019.
51. Campbell JR, Al-Jahdali H, Bah B, et al. Safety and efficacy of rifampin or isoniazid among people with Mycobacterium tuberculosis infection and living with human immunodeficiency virus or other health conditions: posthoc analysis of two randomized Clin Infect Dis. 2021;73(9):e3545-e54. doi:10.1093/cid/ ciaa1169.
52. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–255. doi:10.7326/M17-0609.
53. Ronald LA, Campbell JR, Rose C, et Estimated impact of World Health Organization latent tuberculosis screening guidelines in a region with a low tuberculosis incidence: retrospective cohort study. Clin Infect Dis. 2019;69(12):2101–2108. doi:10.1093/cid/ciz188.
54. World Health Organization. TB country regional and global World Health Organization. Accessed December 7, 2021, 2021. https://worldhealthorg.shinyapps.io/tb_profiles/.
55. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–1278. doi:1016/S1473-3099(16)30216-X.
56. Rustage K, Lobe J, Hayward SE, et Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. Lancet Infect Dis. 2021; 21(12):1701–12. doi:10.1101/2021.06.09.21258452
57. Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ. Initiation and completion rates for latent tuberculosis infection treatment: a systematic BMC Infect Dis. 2016;16:204. doi:10.1186/s12879-016-1550-y.
58. Malekinejad M, Parriott A, Viitanen AP, Horvath H, Marks SM, Kahn JG. Yield of community-based tuberculosis targeted testing and treatment in foreign-born populations in the United States: a systematic PLoS One. 2017;12(8):e0180707. doi:10.1371/journal.pone.0180707.
59. Pontarelli A, Marchese V, Scolari C, et Screening for active and latent tuberculosis among asylum seekers in Italy: A retrospective cohort analysis. Travel Med Infect Dis. 2019;27:39–45. doi:10.1016/j.tmaid.2018.10.015.
60. Ahmed S, Shommu NS, Rumana N, Barron GR, Wicklum S, Turin TC. Barriers to access of primary healthcare by immigrant populations in Canada: a literature J Immigr Minor Health. 2016;18(6):1522–1540. Decdoi:10.1007/s10903-015-0276-z.
61. Al Shamsi H, Almutairi AG, Al Mashrafi S, Al Kalbani T. Implications of language barriers for healthcare: a systematic Oman Med J. 2020;35(2):e122. doi:10.5001/omj.2020.40.
62. Seedat F, Hargreaves S, Nellums LB, Ouyang J, Brown M, Friedland How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. Lancet Infect Dis. 2018;18(9):e259–e271. doi:10.1016/S1473-3099(18)30117-8.
63. Gao J, Berry NS, Taylor D, Venners SA, Cook VJ, Mayhew M. Knowledge and perceptions of latent tuberculosis infection among Chinese immigrants in a Canadian urban Int J Family Med. 2015;2015:546042. doi:10.1155/2015/546042.
64. Coreil J, Lauzardo M, Heurtenou M. Cultural feasibility assessment of tuberculosis prevention among persons of Haitian origin in South Florida. J Immigr Health. 2004;6(2):63–69. doi:1023/B:-JOIH.0000019166.80968.70.
65. Hall J, Kabir TM, Shih P, Degeling C. Insights into culturally appropriate latent tuberculosis infection (LTBI) screening in NSW: perspectives of Indian and Pakistani Aust N Z J Public Health. 2020;44(5):353–359. doi:10.1111/1753-6405.13021.
66. Nordstoga I, Drage M, Steen TW, Winje Wanting to or having to – a qualitative study of experiences and attitudes to- wards migrant screening for tuberculosis in Norway. BMC Public Health. 2019;19(1):796. doi:10.1186/s12889-019-7128-z.
67. Spruijt I, Haile DT, van den Hof S, et al. Knowledge, attitudes, beliefs, and stigma related to latent tuberculosis infection: a qualitative study among Eritreans in the Netherlands. BMC Public Health. 2020;20(1):1602. doi:1186/s12889-020-09697-z.
68. Spruijt I, Haile DT, Erkens C, et al. Strategies to reach and motivate migrant communities at high risk for TB to participate in a latent tuberculosis infection screening program: a community-engaged, mixed methods study among BMC Public Health. 2020;20(1):315. doi:10.1186/s12889-020-8390-9.
69. Spruijt I, Tesfay Haile D, Suurmond J, et al. Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods Eur  Respir  J.  2019;54(5):1900861.  doi:10.1183/13993003.00861-2019.
70. Ikram S, O’Brien K, Rahman A, Potter J, Burman M, Kunst H. P204 – Barriers and facilitators to delivering latent tuberculosis infection (LTBI) screening and treatment to recent migrants: a survey of providers in a high prevalence TB setting in the UK. Thorax.  2019;74(Suppl  2):A199–A200.  doi:10.1183/13993003. congress-2020.508.
71. Nguyen Truax F, Morisky D, Low J, Carson M, Girma H, Nyamathi A. Non-completion of latent tuberculosis infection treatment among Vietnamese immigrants in Southern California: A retrospective Public Health Nurs. 2020;37(6):846–853. doi:10.1111/phn.12798.
72. Bennett RJ, Brodine S, Waalen J, Moser K, Rodwell Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012. Am J Public Health. 2014;104(4):e95–e102. doi:10.2105/ AJPH.2013.301637.
73. Jimenez-Fuentes MA, de Souza-Galvao ML, Mila Auge C, Solsona Peiro J, Altet-Gomez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant Int J Tuberc Lung Dis. 2013;17(3):326–332. doi:10.5588/ijtld.12.0510.
74. Spruijt I, Erkens C, Suurmond J, et al. Implementation of latent tuberculosis infection screening and treatment among newly arriving immigrants in the Netherlands: A mixed methods pilot evaluation. PLoS One. 2019;14(7):e0219252. doi:10.1371/journal.pone.0219252.
75. Milinkovic DA, Birch S, Scott F, et Low prioritization of latent tuberculosis infection – a systemic barrier to tuberculosis control: a qualitative study in Ontario, Canada. Int J Health Plann Manage. 2019;34(1):384–395. doi:10.1002/hpm.2670.
76. Wieland ML, Weis JA, Yawn BP, et al. Perceptions of tubercu- losis among immigrants and refugees at an adult education cen- ter: a community-based participatory research approach. J Immigr Minor Health. 2012;14(1):14–22. doi:10.1007/s10903-010-9391-z.
77. Berrocal-Almanza LC, Botticello J, Piotrowski H, et al. Engaging with civil society to improve access to LTBI screening for new migrants in England: a qualitative Int J Tuberc Lung Dis. 2019;23(5):563–570. doi:10.5588/ijtld.18.0230.
78. Gany FM, Trinh-Shevrin C, Changrani J. Drive-by readings: a creative strategy for tuberculosis control among Am J Public Health . 2005 ; 95 ( 1 ) : 117 – 119 . doi: 10.2105/ AJPH.2003.019620.
79. Erkens CGM, Slump E, Verhagen M, et al. Monitoring latent tuberculosis infection diagnosis and management in the Eur  Respir  J .  2016;47(5):1492–1501. doi:10.1183/13993003.01397-2015.
80. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006;174(6):717–721. doi:10.1164/rccm.200510-1667OC.
81. O’Brien K, Ikram S, Burman M, Rahman A, Kunst H. P202 – Evaluation of a latent tuberculosis infection screening and treatment programme for recent Thorax. 2019;74(Suppl 2):A199.
82. Brewin P, Jones A, Kelly M, et al. Is screening for tuberculosis acceptable to immigrants? A qualitative study. J Public Health (Oxf). 2006;28(3):253–260. doi:1093/pubmed/fdl031.
83. Gustavson G, Narita M, Gardner Toren Reporting of latent TB infection among non-US-born persons adjusting their im- migration status to permanent residents: an opportunity to enhance TB prevention. J Public Health Manag Pract. 2022; 28(2):184–7. doi:10.1097/PHH.0000000000001405.
84. Atchison C, Zenner D, Barnett L, Pareek Treating latent TB in primary care: a survey of enablers and barriers among UK General Practitioners. BMC Infect Dis. 2015;15:331. doi:10.1186/s12879-015-1091-9.
85. LoBue PA, Moser K, Catanzaro Management of tuberculosis in San Diego County: a survey of physicians’ knowledge, attitudes and practices. Int J Tuberc Lung Dis. //2001;5(10):933–938.
86. Pareek M, Abubakar I, White PJ, Garnett GP, Lalvani A. Tuberculosis screening of migrants to low-burden nations: in- sights from  evaluation  of  UK    Eur  Respir  J. 2011;37(5):1175–1182. doi:10.1183/09031936.00105810.
87. Waldorf B, Gill C, Crosby SS. Assessing adherence to accepted national guidelines for immigrant and refugee screening and vaccines in an urban primary care practice: a retrospective chart review. J Immigr Minor Health. 2014;16(5):839–845. doi:10.1007/s10903-013-9808-6.
88. Hargreaves S, Nellums LB, Johnson C, et Delivering multi-disease screening to migrants for latent TB and blood-borne viruses in an emergency department setting: A feasibility study. Travel  Med  Infect  Dis.  2020;36:101611.  doi:10.1016/j.tmaid.2020.101611.
89. Carvalho AC, Saleri N, El-Hamad I, et al. Completion of screening for latent tuberculosis infection among immigrants. Epidemiol Infect. 2005;133(1):179–185. doi:1017/s0950268804003061.
90. Gardam M, Verma G, Campbell A, Wang J, Khan Impact of the patient-provider relationship on the survival of foreign born outpatients with  tuberculosis.  J  Immigr  Minor  Health. 2009;11(6):437–445. doi:10.1007/s10903-008-9221-8.
91. Goldberg SV, Wallace J, Jackson JC, Chaulk CP, Nolan CM. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis. 2004;8(1):76–82.
92. Ailinger RL, Martyn D, Lasus H, Lima Garcia The effect of a cultural intervention on adherence to latent tuberculosis infection therapy in Latino immigrants. Public Health Nurs. 2010;27(2):115–120. doi:10.1111/j.1525-1446.2010.00834.x.
93. Boga JA, Casado L, Fernandez-Suarez J, et al. Screening program for imported diseases in immigrant women: analysis and implications from a gender-oriented Am J Trop Med Hyg. 2020;103(1):480–484. doi:10.4269/ajtmh.19-0687.
94. Bil JP, Schrooders PA, Prins M, et al. Integrating hepatitis B, hepatitis C and HIV screening into tuberculosis entry screening for migrants in the Netherlands, 2013 to Euro Surveill. 2018;23(11):pii=17-00491.   doi:10.2807/1560-7917.ES.2018.23. 11.17-00491.
95. Cuomo G, Franconi I, Riva N, et al. Migration and health: a retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived mi- grants screened at the Infectious Diseases Unit of Modena, J  Infect  Public  Health.  2019;12(2):200–204.  doi:10.1016/j.jiph.2018.10.004.
96. Hargreaves S, Seedat F, Car J, et Screening for latent TB, HIV, and hepatitis B/C in new migrants in a high prevalence area of London, UK: a cross-sectional study. Clinical Trial. BMC Infect Dis. 2014;14(1):657. doi:10.1186/s12879-014-0657-2.
97. Barss L, Moayedi-Nia S, Campbell JR, Oxlade O, Menzies D. Interventions to reduce losses in the cascade of care for latent tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020;24(1):100–109. doi:10.5588/ijtld.19.0185.
98. Griffiths C, Sturdy P, Brewin P, et al. Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled Lancet. 2007;369(9572):1528–1534. doi:10.1016/S0140-6736(07)60707-7.
99. Miller AP, Malekinejad M, Horvath H, Blodgett JC, Kahn JG, Marks SM. Healthcare facility-based strategies to improve tuberculosis testing and linkage to care in non-U.S.-born population in  the  United  States:  a  systematic  review.  PLoS  One. 2019;14(9):e0223077. doi:10.1371/journal.pone.0223077.
100. Wieland ML, Nigon JA, Weis JA, Espinda-Brandt L, Beck D, Sia Sustainability of a tuberculosis screening program at an adult education center through community-based participatory research. J Public Health Manag Pract. 2019;25(6):602–605. doi:10.1097/PHH.0000000000000851.
101. Essadek HO, Mendioroz J, Guiu IC, et Community strategies to tackle tuberculosis according to the WHO region of origin of immigrant communities. Public Health Action. 2018;8(3):135 doi:10.5588/pha.18.0011.
102. Walker CL, Duffield K, Kaur H, Dedicoat M, Gajraj R. Acceptability of latent tuberculosis testing of migrants in a college environment in Public Health. 2018;158:55–60. doi:10.1016/j.puhe.2018.02.004.
103. Hovell MF, Schmitz KE, Blumberg EJ, Hill L, Sipan C, Friedman L. Lessons learned from two interventions designed to increase adherence to LTBI treatment in Latino youth. Contemp Clin Trials Commun. Dec. 2018;12:129–136. doi:10.1016/j. conctc.2018.08.002.
104. Einterz EM, Younge O, Hadi C. The impact of a public health department’s expansion from a one-step to a two-step refugee screening process on the detection and initiation of treatment of latent tuberculosis. Public Health. 2018;159:27–30. doi:10.1016/j.puhe.2018.03.008.
105. Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis. 2016;16:257. doi:10.1186/s12879-016-1549-4.
106. Villa S, Ferrarese M, Sotgiu G, et al. Latent tuberculosis infection treatment completion while shifting prescription from isoniazid-only to rifampicin-containing regimens: a two-decade experience in Milan, Italy. JCM. 2019;9(1):101. doi:10.3390/jcm9010101.
107. Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med. 2018;55(2):244 doi:10.1016/j.amepre.2018.04.030.
108. Diefenbach-Elstob TR, Alabdulkarim B, Deb-Rinker P, et al. Risk of latent and active tuberculosis infection in travellers: a systematic review and meta-analysis. J Travel Jan. 2021;28(1). doi:10.1093/jtm/taaa214.
109. Angell SY, Cetron Health disparities among travelers visiting friends and relatives abroad. Ann Intern Med. 2005;142:67– 72. doi:10.7326/0003-4819-142-1-200501040-00013.
110. Bacaner N, Stauffer B, Boulware DR, Walker PF, Keystone JS. Travel medicine considerations for North American immigrants visitng friends and JAMA. 2004;291(23):2856–2864. doi:10.1001/jama.291.23.2856.
111. Fenner L, Weber R, Steffen R, Schlagenhauf P. Imported infec- tious disease and purpose of travel, Emerg Infect Dis. 2007;13(2):217–222. doi:10.3201/eid1302.060847.
112. Gautret P, Cramer JP, Field V, et al. Infectious diseases among travellers and migrants in Europe, EuroTravNet 2010. Euro Surveill. 2012;17(26):16–26.
113. McCarthy Asian immigrant tuberculosis – the effect of visiting Asia. Br J Dis Chest. 1984;78:248–253.
114. Ormerod LP, Green RM, Gray S. Are there still effects on Indian Subcontinent ethnic tuberculosis of return visits?: a longitudinal study 1978-97.  J  Infect.  2001;43(2):132–134.  doi:1053/jinf.2001.0872.
115. Wikman-Jorgensen P, Lopez-Velez R, Llenas-Garcia J, et al. Latent and active tuberculosis infections in migrants and travellers: a retrospective analysis from the Spanish + REDIVI collaborative network. Travel Med Infect Dis. 2020;36:101460. doi:10.1016/j.tmaid.2019.07.016.
116. Kik SV, Mensen M, Beltman M, et al. Risk of travelling to the country of origin for tuberculosis among immigrants living in a low-incidence country. Int J Tuberc Lung Dis. 2011;15(1):38–43.
117. Saiman L, Gabriel PS, Schulte J, Vargas MP, Kenyon T, Onorato Risk factors for latent tuberculosis infection among children in New York City. Pediatrics. 2001;107(5):999–1003. doi:1542/ peds.107.5.999.
118. Young J, O’Connor ME. Risk factors associated with latent tuberculosis infection in Mexican American children. Pediatrics. 2005;115(6):e647-53. doi:1542/peds.2004-1685.
119. Tan M, Menzies D, Schwartzman K. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness anal- BMC Public Health. 2008;8:201. doi:10.1186/1471-2458-8-201.
120. Campbell JR, Johnston JC, Sadatsafavi M, Cook VJ, Elwood RK, Marra F. Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to PLoS One. 2017;12(10):e0186778. doi:10.1371/journal.pone.0186778.
121. Dale KD, Abayawardana MJ, McBryde ES, Trauer JM, Carvalho Modeling the cost-effectiveness of latent tuberculosis screening and treatment strategies in recent migrants to a low-incidence setting. Am  J  Epidemiol.  2022;91(2):255–70. doi:10.1093/aje/kwab150.
122. Jo Y, Shrestha S, Gomes I, et Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York, and Texas. Clin Infect Dis. 2021;73(9):e3476–e82. doi:10.1093/cid/ciaa857.
123. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness    Lancet  Infect  Dis. 2011;11(6):435–444. doi:10.1016/S1473-3099(11)70069-X.

Switch To: Français